Logo

PharmaShots Weekly Snapshots (July 04 – 08, 2022)

Share this
PharmaShots Weekly Snapshots (July 04 – 08, 2022)

PharmaShots Weekly Snapshots (July 04 – 08, 2022)

Bausch + Lomb and Novaliq Report the NDA Submission of NOV03 (perfluorohexyloctane) to the US FDA for Dry Eye Disease Associated with Meibomian Gland Dysfunction

Published: July 8, 2022 | Tags: Bausch + Lomb, Novaliq, NOV03, perfluorohexyloctane, Dry Eye Disease, Meibomian Gland Dysfunction, Regulatory, US, FDA, NDA

ADC Entered into an Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in EU and Select International Territories

Published: July 8, 2022 | Tags: ADC, Sobi, Zynlonta, loncastuximab tesirine-lpyl, Pharma EU, International Territories

EarlySign Collaborated with Roche to Develop AI Solution for Early Detection of Lung Cancer

Published: July 8, 2022 | Tags: EarlySign, Roche, AI Solution, Lung Cancer, Pharma, LungFlag

Alvotech Initiates (ALVOEYE) Clinical Study of AVT06, a Proposed Biosimilar to Eylea for Eye Disorders

Published: July 8, 2022 | Tags: Alvotech, AVT06, Biosimilar, Eylea, Eye Disorders, Clinical Trial, ALVOEYE Clinical Study, 

Portage Acquires Tarus and Adds Four Adenosine Products to its Pipeline

Published: July 8, 2022 | Tags: Portage, Tarus, PORT-6, PORT-7, PORT-8, PORT-9, Acquire

SD Biosensor and SJL Partners Entered into a Definitive Merger Agreement to Acquire Meridian for ~$1.53B

Published: July 8, 2022 | Tags: SD Biosensor, SJL, Meridian, M&A, ~$1.53B, Consortium, Acquire

Lysogene Presents Preliminary Results of LYS-SAF302 in P-II/III (AAVance) Trial for the Treatment of MPS IIIA in Children at ADVANCE 2022

Published: July 7, 2022 | Tags: Lysogene, LYS-SAF302, MPS IIIA, Clinical Trial, P-II/III, AAVance Trial, ADVANCE, 2022

BeiGene Collaborated with InnoRNA to Discover Novel mRNA-LNP Therapies

Published: July 7, 2022 | Tags: BeiGene, InnoRNA, Novel mRNA Therapies, Pharma

Calithera Reports the First Patient Enrollment of Sapanisertib in P-II Clinical Trial for NRF2-Mutated Squamous Non-Small Cell Lung Cancer

Published: July 7, 2022 | Tags: Calithera, Sapanisertib, NRF2-Mutated, Squamous, Non-Small Cell Lung Cancer, P-II Clinical Trial

Exelixis Entered into an Exclusive License Agreement with Ryvu to Develop Novel STING Agonist-Based Targeted Cancer Therapies

Published: July 7, 2022 | Tags: Exelixis, Ryvu, Novel STING Agonist-Based Targeted, Cancer, Therapies, Pharma

Brii Biosciences Launches Amubarvimab/Romlusevimab Combination in China for the Treatment of COVID-19

Published: July 7, 2022 | Tags: Brii Biosciences, Amubarvimab, Romlusevimab, Pharma, COVID-19, China, P-III, ACTIV-2

DiaMedica Reports the US FDA’s Clinical Hold on the P-II/III (ReMEDy2) Trial of DM199 for the Treatment of Acute Ischemic Stroke

Published: July 7, 2022 | Tags: DiaMedica, DM199, Acute Ischemic Stroke, Regulatory, US, FDA, P-II/II, ReMEDy1, ReMEDy2

Nordic Nanovector to Discontinue P-IIb (PARADIGME) Trial of Betalutin in 3L Treatment of Relapsed and Anti-CD20 Refractory Follicular Lymphoma

Published: July 6, 2022 | Tags: Nordic Nanovector, Betalutin, Follicular Lymphoma, Clinical Trial, P-IIb, PARADIGME Trial, 

BioArctic Partner Eisai Report the US FDA Acceptance of BLA for Lecanemab to Treat Alzheimer's Disease

Published: July 6, 2022 | Tags: BioArctic, Eisai, Lecanemab, Alzheimer's Disease, US, FDA, BLA

Urovant Entered into an Exclusive License Agreement with Pierre Fabre Médicament to Commercialize Vibegron for Overactive Bladder

Published: July 6, 2022 | Tags: Urovant, Pierre Fabre Médicament, Vibegron, Overactive Bladder, Pharma

Genentech Reports the US FDA Acceptance of BLA and Granted Priority Review of Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma

Published: July 6, 2022 | Tags: Genentech, Mosunetuzumab, Follicular Lymphoma, US, FDA, BLA, Priority Review

Sanofi Signs an Exclusive Worldwide Collaboration Agreement with Skyhawk to Discover Novel Small Molecules for Oncology and Immunology Targets

Published: July 6, 2022 | Tags: Sanofi, Skyhawk, Novel Small Molecules, Oncology, Immunology, Pharma, SkySTAR Platform

AstraZeneca to Acquire TeneoTwo for ~$1.27B

Published: July 6, 2022 | Tags: AstraZeneca, TeneoTwo, TNB-486, Calquence, acalabrutinib, B-Cell Haematologic Malignancies, ~$1.27B, Acquire

Astellas Entered into a Research Agreement with Mogrify for In Vivo Regenerative Therapy in Sensorineural Hearing Loss

Published: July 5, 2022 | Tags: Astellas, Mogrify, Sensorineural Hearing Loss, In Vivo Regenerative Therapy, Biotech

EditForce Entered into a License Agreement with Mitsubishi Tanabe Pharma to Develop and Commercialize Gene Therapies for Central Nervous System

Published: July 5, 2022 | Tags: EditForce, Mitsubishi Tanabe Pharma, Gene Therapies, Central Nervous System, Biotech, PPR Protein Platform Technology

Livemetric Receives the US FDA’s Clearance for LiveOne Blood Pressure Monitoring Technology

Published: July 5, 2022 | Tags: Livemetric, LiveOne, Blood Pressure Monitoring Technology, Hypertension, Cardiovascular Diseases, Regulatory, US, FDA, Clearance

Pfizer’s Cibinqo (abrocitinib) Receives Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Published: July 5, 2022 | Tags: Pfizer, Cibinqo, abrocitinib, Atopic Dermatitis, Regulatory, Health Canada, Approval

JW Therapeutics Reports Initiation of P-I clinical study for JWATM204 to Treat Advanced Hepatocellular Carcinoma

Published: July 5, 2022 | Tags: JW Therapeutics, JWATM204, Advanced Hepatocellular Carcinoma, Clinical Trial, P-I clinical study

Arctic Vision Reports the First Patient Enrollment in P-III Clinical Trial of ARVN003 for the Treatment of Presbyopia

Published: July 5, 2022 | Tags: Arctic Vision, ARVN003, Presbyopia, Clinical Trial, P-III Clinical Trial, VISION-1, MicroLine

Abbisko Therapeutics Reports the Completion of First Patient Dosing of ABSK061 in P-I (ABSK061-101) Clinical Trial for the Treatment of Solid Tumors

Published: July 4, 2022 | Tags: Abbisko Therapeutics, ABSK061, Solid Tumors, Clinical Trial, P-I, ABSK061-101

Oxford Biomedica Signs Three Year Master Services & Development Agreement with Astrazeneca to Manufacture COVID-19 Vaccines

Published: July 4, 2022 | Tags: Oxford Biomedica, Astrazeneca, COVID-19 Vaccines, Master Services, Pharma, COVID-19 Development Agreement

Nurix Therapeutics Receives the US FDA’s IND Clearance for NX-1607 to Treat Advanced Malignancies

Published: July 4, 2022 | Tags: Nurix Therapeutics, US FDA, IND, Clearance, NX-1607, Advanced Malignancies

Innovent Reports the First Patient Dosing of IBI112 in a P-II Clinical Study for the Treatment of Moderate-to-Severe Active Ulcerative Colitis

Published: July 4, 2022 | Tags: Innovent, IBI112, Active Ulcerative Colitis, Clinical Trial, P-II, Clinical study

Seagen Presents Results of Tukysa (tucatinib) + Trastuzumab in P-II (MOUNTAINEER) Trial for HER2-Positive Metastatic Colorectal Cancer at ESMO 2022

Published: July 4, 2022 | Tags: Seagen, Tukysa, tucatinib, Trastuzumab, HER2-Positive, Metastatic Colorectal Cancer, Clinical Trial, P-II, MOUNTAINEER Trial, ESMO, 2022

AstraZeneca Presents Results of Imfinzi in P-III (HIMALAYA) and (TOPAZ-1) Trial for Liver and Biliary Tract Cancer at EASL 2022 and ESMO World GI 2022

Published: July 4, 2022 | Tags: AstraZeneca, Imfinzi, Liver, Biliary Tract Cancer, Clinical Trial, P-III, HIMALAYA, TOPAZ-1 Trial, EASL, 2022, ESMO, World GI, 2022

Related Post: PharmaShots Weekly Snapshots (June 27 – July 01, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions